...
lctx-img

Lineage Cell Therapeutics Inc, Common Stock

LCTX

ASQ

$0.558

+$0.06

(11.95%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$110.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.10M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.28
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.48 L
$1.61 H
$0.558

About Lineage Cell Therapeutics Inc, Common Stock

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLCTXSectorS&P500
1-Week Return10.28%-2.12%-3%
1-Month Return-13%-3.42%-0.73%
3-Month Return-40.64%-11.13%2.87%
6-Month Return-37.6%-5.74%7.17%
1-Year Return-44.75%3.97%25.31%
3-Year Return-78.29%1.05%28.38%
5-Year Return-6.17%34.37%81.89%
10-Year Return-82.04%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.48M773.00K3.90M14.70M8.95M[{"date":"2019-12-31","value":10.05,"profit":true},{"date":"2020-12-31","value":5.26,"profit":true},{"date":"2021-12-31","value":26.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":60.84,"profit":true}]
Cost of Revenue412.00K385.00K1.43M728.00K671.00K[{"date":"2019-12-31","value":28.89,"profit":true},{"date":"2020-12-31","value":27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":51.05,"profit":true},{"date":"2023-12-31","value":47.05,"profit":true}]
Gross Profit1.07M388.00K2.47M13.97M8.27M[{"date":"2019-12-31","value":7.63,"profit":true},{"date":"2020-12-31","value":2.78,"profit":true},{"date":"2021-12-31","value":17.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.21,"profit":true}]
Gross Margin72.12%50.19%63.40%95.05%92.50%[{"date":"2019-12-31","value":75.88,"profit":true},{"date":"2020-12-31","value":52.81,"profit":true},{"date":"2021-12-31","value":66.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.32,"profit":true}]
Operating Expenses39.94M26.84M51.68M36.49M33.01M[{"date":"2019-12-31","value":77.29,"profit":true},{"date":"2020-12-31","value":51.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.62,"profit":true},{"date":"2023-12-31","value":63.87,"profit":true}]
Operating Income(38.88M)(26.45M)(49.21M)(22.52M)(24.73M)[{"date":"2019-12-31","value":-3887600000,"profit":false},{"date":"2020-12-31","value":-2644700000,"profit":false},{"date":"2021-12-31","value":-4921100000,"profit":false},{"date":"2022-12-31","value":-2252000000,"profit":false},{"date":"2023-12-31","value":-2473300000,"profit":false}]
Total Non-Operating Income/Expense21.33M5.56M5.94M(2.46M)3.08M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":26.08,"profit":true},{"date":"2021-12-31","value":27.87,"profit":true},{"date":"2022-12-31","value":-11.55,"profit":false},{"date":"2023-12-31","value":14.44,"profit":true}]
Pre-Tax Income(19.23M)(21.92M)(43.27M)(25.81M)(23.28M)[{"date":"2019-12-31","value":-1923400000,"profit":false},{"date":"2020-12-31","value":-2192400000,"profit":false},{"date":"2021-12-31","value":-4327000000,"profit":false},{"date":"2022-12-31","value":-2581200000,"profit":false},{"date":"2023-12-31","value":-2328200000,"profit":false}]
Income Taxes(7.41M)(1.24M)(4.71M)541.00K(1.80M)[{"date":"2019-12-31","value":-1369.13,"profit":false},{"date":"2020-12-31","value":-229.02,"profit":false},{"date":"2021-12-31","value":-869.87,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-333.27,"profit":false}]
Income After Taxes(11.83M)(20.68M)(38.56M)(26.35M)(21.48M)[{"date":"2019-12-31","value":-1182700000,"profit":false},{"date":"2020-12-31","value":-2068500000,"profit":false},{"date":"2021-12-31","value":-3856400000,"profit":false},{"date":"2022-12-31","value":-2635300000,"profit":false},{"date":"2023-12-31","value":-2147900000,"profit":false}]
Income From Continuous Operations(26.64M)(20.68M)(43.27M)(26.35M)(21.48M)[{"date":"2019-12-31","value":-2664100000,"profit":false},{"date":"2020-12-31","value":-2068500000,"profit":false},{"date":"2021-12-31","value":-4327000000,"profit":false},{"date":"2022-12-31","value":-2635300000,"profit":false},{"date":"2023-12-31","value":-2147900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(11.83M)(20.68M)(38.56M)(26.35M)(21.49M)[{"date":"2019-12-31","value":-1182700000,"profit":false},{"date":"2020-12-31","value":-2068500000,"profit":false},{"date":"2021-12-31","value":-3856400000,"profit":false},{"date":"2022-12-31","value":-2635300000,"profit":false},{"date":"2023-12-31","value":-2148600000,"profit":false}]
EPS (Diluted)(0.05)(0.14)(0.26)(0.15)(0.13)[{"date":"2019-12-31","value":-5,"profit":false},{"date":"2020-12-31","value":-14,"profit":false},{"date":"2021-12-31","value":-26,"profit":false},{"date":"2022-12-31","value":-15,"profit":false},{"date":"2023-12-31","value":-13,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LCTX
Cash Ratio 2.36
Current Ratio 2.48

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LCTX
ROA (LTM) -12.86%
ROE (LTM) -35.04%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LCTX
Debt Ratio Lower is generally better. Negative is bad. 0.33
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.67

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LCTX
Trailing PE NM
Forward PE NM
P/S (TTM) 19.88
P/B 1.86
Price/FCF NM
EV/R 10.67
EV/Ebitda NM

FAQs

What is Lineage Cell Therapeutics Inc share price today?

Lineage Cell Therapeutics Inc (LCTX) share price today is $0.558

Can Indians buy Lineage Cell Therapeutics Inc shares?

Yes, Indians can buy shares of Lineage Cell Therapeutics Inc (LCTX) on Vested. To buy Lineage Cell Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LCTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lineage Cell Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Lineage Cell Therapeutics Inc (LCTX) via the Vested app. You can start investing in Lineage Cell Therapeutics Inc (LCTX) with a minimum investment of $1.

How to invest in Lineage Cell Therapeutics Inc shares from India?

You can invest in shares of Lineage Cell Therapeutics Inc (LCTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in LCTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lineage Cell Therapeutics Inc shares
What is Lineage Cell Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Lineage Cell Therapeutics Inc (LCTX) is $1.61. The 52-week low price of Lineage Cell Therapeutics Inc (LCTX) is $0.48.

What is Lineage Cell Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Lineage Cell Therapeutics Inc (LCTX) is

What is Lineage Cell Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lineage Cell Therapeutics Inc (LCTX) is 1.86

What is Lineage Cell Therapeutics Inc dividend yield?

The dividend yield of Lineage Cell Therapeutics Inc (LCTX) is 0.00%

What is the Market Cap of Lineage Cell Therapeutics Inc?

The market capitalization of Lineage Cell Therapeutics Inc (LCTX) is $110.65M

What is Lineage Cell Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Lineage Cell Therapeutics Inc is LCTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top